Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for givosiran (ALN-AS1), an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the prophylaxis of attacks in patients with acute hepatic porphyria (AHP). Breakthrough Therapy designation is granted to expedite the development and review of new drugs that treat serious or life-threatening diseases where preliminary clinical evidence exists in support of substantial benefit over available therapies. The designation is aimed to help ensure that patients with unmet medical needs receive access to new therapies through FDA approval as soon as possible.
“Patients with acute hepatic porphyrias, a family of ultra-rare diseases, suffer from severe neurovisceral attacks often resulting in hospitalization, and chronic, debilitating symptoms that impair daily function. This FDA decision is recognition of both the need for novel therapeutic options and the promising initial results with givosiran,” said Jeff Miller, Vice President, General Manager, Givosiran Program at Alnylam. “We believe givosiran could become a transformative treatment for patients with this devastating and potentially life-threatening disease. Accordingly, we look forward to rapidly advancing this program in collaboration with global regulatory authorities, having also received PRIME designation from the European Medicines Agency earlier this year. We plan to initiate the Phase 3 clinical program with givosiran in late 2017.”
Promising results from the ongoing Phase 1 study of givosiran demonstrating meaningful reductions in the occurrence of porphyria attacks formed the basis of the Breakthrough application. Updated results from this trial will be provided in an oral presentation on June 26, 2017 at the International Congress on Porphyrins and Porphyrias (ICPP) being held in Bordeaux, France.
About Givosiran Phase 1 Study
The ongoing portion of
the Phase 1 study of givosiran (Part C) is being conducted as a
randomized, double-blind, placebo-controlled study. Data presented at
the 2016 American Society of Hematology (ASH) meeting demonstrated
initial evidence for clinical activity with givosiran including
meaningful reductions in both the number and frequency of porphyria
attacks, as well as meaningful reductions in annualized hemin doses
required in patients with acute intermittent porphyria (AIP), the most
common and severe form of AHP. In the first two dose cohorts, givosiran
was found to be generally well tolerated with no drug-related serious
adverse events. In the third dose cohort, which remains blinded, one
death due to acute pancreatitis, considered unlikely related to
givosiran or placebo, was reported after the data transfer date.
About Givosiran
Alnylam is developing givosiran
(formerly known as ALN-AS1), a subcutaneously administered,
investigational RNAi therapeutic targeting aminolevulinic acid synthase
1 (ALAS1) for the treatment of acute hepatic porphyrias, including acute
intermittent porphyria (AIP). AIP is the most common of the porphyrias,
an ultra-rare autosomal dominant disease caused by loss of function
mutations in porphobilinogen deaminase (PBGD), an enzyme in the heme
biosynthesis pathway that can result in accumulation of toxic heme
intermediates, including aminolevulinic acid (ALA) and porphobilinogen
(PBG). Givosiran is an ESC-GalNAc-siRNA conjugate targeting ALAS1, a
liver-expressed, rate-limiting enzyme upstream of PBGD in the heme
biosynthesis pathway. Inhibition of ALAS1 is known to reduce the
accumulation of heme intermediates that cause the clinical
manifestations of AIP. Givosiran has the potential to be a novel
treatment approach for the prevention of recurrent attacks. Givosiran
has previously been granted PRIME designation which was established by
the European Medicines Agency (EMA) to bring treatments to patients
faster by enhancing the EMA’s support for the development of medicines
for diseases where there is an unmet medical need and where early
clinical data show potential to benefit patients. Givosiran has also
been granted Orphan Drug Designations in both the E.U. and the U.S. for
the treatment of acute hepatic porphyrias.
About Acute Hepatic Porphyrias
The porphyrias are a
family of rare metabolic disorders with mostly autosomal dominant
inheritance predominantly caused by a genetic mutation in one of the
eight enzymes responsible for heme biosynthesis. Acute hepatic
porphyrias (AHP) constitute a subset where the enzyme deficiency occurs
within the liver, and includes acute intermittent porphyria (AIP),
hereditary coproporphyria (HCP), and variegate porphyria (VP). Exposure
of AHP patients to certain drugs, dieting, or hormonal changes can
trigger strong induction of aminolevulinic acid synthase 1 (ALAS1),
another enzyme in the heme biosynthesis pathway, which can lead to
accumulation of neurotoxic heme intermediates that precipitate disease
symptoms. Patients with AHP can suffer from a range of symptoms that,
depending on the specific type, can include acute and/or recurrent
life-threatening attacks with severe abdominal pain, peripheral and
autonomic neuropathy, neuropsychiatric manifestations, cutaneous lesions
and possibly paralysis and death if untreated or if there are delays in
treatment. There are no approved treatments for the prevention of
attacks; the only approved treatment for acute attacks is hemin for
injection (Panhematin® or Normosang®), a preparation of heme derived
from human blood. Hemin requires administration through a large vein or
a central intravenous line and is associated with a number of
complications including thrombophlebitis or coagulation abnormalities.
Chronic administration of hemin may result in renal insufficiency, iron
overload, systemic infections (due to the requirement for central venous
access) and, in some instances, tachyphylaxis.
About RNAi
RNAi (RNA interference) is a revolution in
biology, representing a breakthrough in understanding how genes are
turned on and off in cells, and a completely new approach to drug
discovery and development. Its discovery has been heralded as "a major
scientific breakthrough that happens once every decade or so," and
represents one of the most promising and rapidly advancing frontiers in
biology and drug discovery today which was awarded the 2006 Nobel Prize
for Physiology or Medicine. RNAi is a natural process of gene silencing
that occurs in organisms ranging from plants to mammals. By harnessing
the natural biological process of RNAi occurring in our cells, the
creation of a major new class of medicines, known as RNAi therapeutics,
is on the horizon. Small interfering RNA (siRNA), the molecules that
mediate RNAi and comprise Alnylam's RNAi therapeutic platform, target
the cause of diseases by potently silencing specific mRNAs, thereby
preventing disease-causing proteins from being made. RNAi therapeutics
have the potential to treat disease and help patients in a fundamentally
new way.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY)
is leading the translation of RNA interference (RNAi) into a whole new
class of innovative medicines with the potential to transform the lives
of patients who have limited or inadequate treatment options. Based on
Nobel Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach for the treatment of a wide range of
debilitating diseases. Founded in 2002, Alnylam is delivering on a bold
vision to turn scientific possibility into reality, with a robust
discovery platform and deep pipeline of investigational medicines,
including three product candidates that are in late-stage development or
will be in 2017. Looking forward, Alnylam will continue to execute on
its “Alnylam 2020” strategy of building a multi-product,
commercial-stage biopharmaceutical company with a sustainable pipeline
of RNAi-based medicines. For more information about our people, science
and pipeline, please visit www.alnylam.com
and engage with us on Twitter at @Alnylam.
Alnylam Forward Looking Statements
Various statements
in this release concerning Alnylam's future expectations, plans and
prospects, including without limitation, Alnylam's views with respect to
the potential for RNAi therapeutics, including givosiran, its
expectations regarding the timing of clinical studies, including the
initiation of a Phase 3 trial for givosiran following interactions with
regulatory authorities, its expectations regarding scientific and
regulatory support for givosiran from the FDA and EMA and collaborating
with these agencies on the accelerated assessment of givosiran, its
expectations regarding its STAr pipeline growth strategy, and its
“Alnylam 2020” guidance for the advancement and commercialization of
RNAi therapeutics, constitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results and future plans may
differ materially from those indicated by these forward-looking
statements as a result of various important risks, uncertainties and
other factors, including, without limitation, Alnylam's ability to
discover and develop novel drug candidates and delivery approaches,
successfully demonstrate the efficacy and safety of its product
candidates, the pre-clinical and clinical results for its product
candidates, which may not be replicated or continue to occur in other
subjects or in additional studies or otherwise support further
development of product candidates for a specified indication or at all,
actions or advice of regulatory agencies, which may affect the design,
initiation, timing, continuation and/or progress of clinical trials or
result in the need for additional pre-clinical and/or clinical testing,
delays, interruptions or failures in the manufacture and supply of our
product candidates, obtaining, maintaining and protecting intellectual
property, Alnylam's ability to enforce its intellectual property rights
against third parties and defend its patent portfolio against challenges
from third parties, obtaining and maintaining regulatory approval,
pricing and reimbursement for products, progress in establishing a
commercial and ex-United States infrastructure, competition from others
using technology similar to Alnylam's and others developing products for
similar uses, Alnylam's ability to manage its growth and operating
expenses, obtain additional funding to support its business activities,
and establish and maintain strategic business alliances and new business
initiatives, Alnylam's dependence on third parties for development,
manufacture and distribution of products, the outcome of litigation, the
risk of government investigations, and unexpected expenditures, as well
as those risks more fully discussed in the "Risk Factors" filed with
Alnylam's most recent Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission (SEC) and in other filings that
Alnylam makes with the SEC. In addition, any forward-looking statements
represent Alnylam's views only as of today and should not be relied upon
as representing its views as of any subsequent date. Alnylam explicitly
disclaims any obligation, except to the extent required by law, to
update any forward-looking statements.
The scientific information referenced in this news release relating to givosiran is preliminary and investigative. Givosiran has not been approved by the U.S. Food and Drug Administration, European Medicines Agency, or any other regulatory authority and no conclusions can or should be drawn regarding its safety or effectiveness.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170531005331/en/
Contacts:
Christine Regan Lindenboom,
617-682-4340
(Investors and Media)
or
Josh Brodsky,
617-551-8276
(Investors)